Based on these observations, we screened the best peptide candidate having higher intracellular selectivity to c-MYC quadruplex and determined its mode of action to drive apoptotic signalling in cancer cells by monitoring differential expression of the apoptotic markers. This evidence concerns the gene MYC and cancer.